Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Net Income (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Net Income for 6 consecutive years, with -$12.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 13.19% year-over-year to -$12.2 million, compared with a TTM value of -$36.3 million through Sep 2025, down 11.78%, and an annual FY2024 reading of -$26.4 million, up 49.5% over the prior year.
  • Net Income was -$12.2 million for Q3 2025 at Ovid Therapeutics, down from -$4.7 million in the prior quarter.
  • Across five years, Net Income topped out at $176.0 million in Q1 2021 and bottomed at -$26.0 million in Q4 2021.
  • Average Net Income over 5 years is -$2.0 million, with a median of -$12.0 million recorded in 2022.
  • The sharpest move saw Net Income surged 978.71% in 2021, then crashed 154.97% in 2025.
  • Year by year, Net Income stood at -$26.0 million in 2021, then surged by 55.75% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then crashed by 31.4% to -$12.2 million in 2025.
  • Business Quant data shows Net Income for OVID at -$12.2 million in Q3 2025, -$4.7 million in Q2 2025, and -$10.2 million in Q1 2025.